The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials, or ALCHEMIST, was launched today to identify early-stage lung cancer patients with tumors that harbor certain uncommon genetic changes and evaluate whether drug treatments targeted against those changes can lead to improved survival.
Related posts:
- Medicare, NCI announces plans to reinvigorate clinical trials The National Cancer Institute (NCI) has announced major changes to be made in the long-established Clinical Trials Cooperative Group Program that conducts many of the nationwide trials of new cancer therapies. In a major transformation, NCI intends to consolidate the nine groups that currently conduct trials in adult cancer patients into four state-of-the-art entities that […]...
- Medicare Card, NIH study suggests gene variation may shape bladder cancer treatment Medicare Card, NIH study suggests gene variation may shape bladder cancer treatment...
- Medicare, Gene variations linked to lung cancer susceptibility in Asian women An international group of scientists has identified three genetic regions that predispose Asian women who have never smoked to lung cancer. The finding provides further evidence that risk of lung cancer among never-smokers, especially Asian women, may be associated with certain unique inherited genetic characteristics that distinguishes it from lung cancer in smokers....
- Medicare NIH funds four clinical trials to fight antimicrobial resistance The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced four new contracts for large-scale clinical trials that address the problem of antimicrobial resistance. Over the next five to six years, these new clinical trials will evaluate treatment alternatives for diseases for which antibiotics are prescribed most […]...
- Standard aplastic anemia therapy improves patient outcomes better than newer version A comparison clinical study of two aplastic anemia treatments found that ATGAM, currently the only licensed aplastic anemia drug in the United States, improved blood cell counts and survival significantly more than Thymoglobulin, a similar but reportedly more potent treatment. The research was carried out by the National Heart, Lung and Blood Institute (NHLBI), part […]...
- Medicare, New website: Clinical Research Trials and You The National Institutes of Health has created a new website, NIH Clinical Research Trials and You to help people learn more about clinical trials, why they matter, and how to participate....
- Medicare Card, Rare cancers yield potential source of tumor growth Medicare Card, Rare cancers yield potential source of tumor growth...
- Improving Diagnosis Through Precision Medicine Dr. Insel describes how precision medicine may put us on the path to better diagnosis and treatment of mental disorders....
- Medicare, NIH scientists identify possible gene target for treating a form of lymphoma Researchers have identified a mutation in a gene that could lead to targeted therapies for certain lymphoma patients whose cure rates are currently poor. Mutation of the MYD88 gene was found to be one of the most frequent genetic abnormalities in a form of cancer known as diffuse large B cell lymphoma. MYD88 encodes a […]...
- Medicare Card, Avoid ‘Free Trials’ Scams Medicare Card, Avoid 'Free Trials' Scams...
- Therapeutics for Rare and Neglected Diseases Program announces next round of drug development projects Researchers will begin drug development projects for rare and neglected diseases that include potential treatments for a musculoskeletal disorder, a cognitive dysfunction disorder, a virus that affects the central nervous system of newborns, a parasitic worm infection, a form of muscular dystrophy and a rare lung disease....
- Medicare Card, Compounds activate key cancer enzyme to interfere with tumor formation Medicare Card, Compounds activate key cancer enzyme to interfere with tumor formation...
- Medicare Future? Pathways that Can Repair Brca1 Cancer Gene Mutation Clarified in Mice In a new study in mice, scientists have compensated for mutations in the Brca1 gene that can lead to cancer by deleting a second gene, which then lessens the probability of cancer. Mice Brca1-associated mammary tumors have significant similarities to human BRCA1- associated (BReast CAncer 1, early onset) breast cancer in regard to tumor aggressiveness, high incidence, mutations and genetic instability. The study, led by scientists at National Cancer Institute (NCI), part of the National Institutes of Health, and their colleagues, appeared online April 1, 2010 and in print April 16, 2010, in the journal Cell....
- Medicare Card, Skin Cancer and What You Need to Know Medicare Card, Skin Cancer and What You Need to Know...
- Medicare Card, Lung Cancer and How to Reduce Your Risk Medicare Card, Lung Cancer and How to Reduce Your Risk...